No description available.

No description available.

We have used the chicken retina as a model for investigating cell cycle regulation and cell fate commitment during central nervous system development. This thesis focuses on the characterization of and commitment to the horizontal cell fate in the retina. Horizontal cells are interneurons that provide intraretinal signal processing prior to information relay to the brain. We have identified molecular markers that selectively distinguish the three subtypes of horizontal cells, previously described in the chicken retina based on morphology. Subtype specific birth-dating revealed that horizontal cell subtypes are generated consecutively by biased progenitors that are sensitive to the inhibitory effects of follistatin. Follistatin stimulates proliferation in progenitors by repressing the differentiation signal of activin. Initially, injection of follistatin led to a decrease in committed horizontal cells but as the inhibitory effect dissipated it resulted in an increased number of horizontal cells. During development committed horizontal cell progenitors migrate to the vitreal side of the retina where they become arrested in G2-phase for approximately two days. When the arrest is overcome the horizontal cell progenitors undergo ectopic mitosis followed by migration to their designated layer. The G2-phase arrest is not triggered or maintained by any of the classic G2-arrest pathways such as DNA damage or stress. Nevertheless, we show that the cyclin B1-Cdk1 complex has a central role in maintaining this G2-phase arrest. Two transcription factors, FoxN4 and Ptf1a, are required for the generation of horizontal cells. We show that these factors are also sufficient to promote horizontal cell fate. Overexpression of FoxN4 and Ptf1a resulted in an overproduction of horizontal- and amacrine cells at the expense of ganglion- and photoreceptor cells. We identified Atoh7, a transcription factor required for the generation of ganglion cells, as a Ptf1a transcriptional target for downregulation. Our data support a common horizontal/amacrine lineage separated from the ganglion/photoreceptor lineage by the action of Ptf1a. In conclusion, these data describe several novel characteristics of horizontal cells enhancing our understanding of neural development and cell fate commitment.

Thesis (Ph. D.)--University of Washington, 1998. / Vita. Includes bibliographical references (leaves [103]-137).

Thesis (Ph. D.)--University of Washington, 1999. / Vita. Includes bibliographical references (leaves 83-112).

Thesis (Ph. D.)--University of Washington, 1999. / Vita. Includes bibliographical references (leaves 92-115).

Thesis (Ph. D.)--University of Washington, 2004. / Vita. Includes bibliographical references (leaves 106-122).

Aim: Cisplatin is the first platinum drug that shows promising anti-tumor effect clinically. Oxaliplatin, a third-generation platinum drug that incorporates a diaminocyclohexane (DACH) structural entity, can overcome cisplatin resistance. R,R-5, a novel platinum compound that integrates the DACH entity with a demethylcantharidin (DMC) component that is derived from a traditional Chinese medicine (TCM) , can also overcome cisplatin resistance. The principal objectives of this study was to investigate in detail, the effect of these compounds at the antephase and G2 checkpoints of the cell cycle, and to establish the relationship (if any) between different structural entities with checkpoint activation. The ultimate aim of the study was to ascertain the potential for the development of novel checkpoint abrogators as anti-tumor agents. / Background: A common procedure in current cancer chemotherapy is to induce genomic stress in cancer cells, leading to irreparable DNA damage and eventually cell death. However, there are several DNA repair mechanisms in cancer cells to maintain genomic stability, which require cell cycle checkpoints to stop cell proliferation for DNA damage repair, thereby avoiding errors in cellular events like DNA replication, transcription and mitosis. Among these cell cycle checkpoints, antephase and G2 checkpoints are two gate checkpoints for mitosis. Abrogation of G2 checkpoint has been reported to give rise to synergistic cytotoxic effect with DNA damaging agents, representing a means of circumventing drug resistance in chemotherapy. / Conclusions: Acute stress to cisplatin can activate the MMR/c-Abl/MEKK1/p38MAPK pathway, leading to the activation of antephase checkpoint, and stop cells from entering mitosis immediately. DACH-containing platinum compound oxaliplatin fails to activate this antephase checkpoint. However, both cisplatin and oxaliplatin can activate the G2 checkpoint, which can be abrogated by DMC. In contrast, RR-5 can bypass both the antephase and G2 checkpoints. In summary, novel TCM-platinum compound R,R-5 can bypass mitotic DNA damage checkpoints in cancer cells and thus has the potential for further development as an anti-cancer drug. / Methods: Microarray analysis was used to detect gene transcription profiles after drug treatments. The activation of mitotic checkpoints was inspected by counting mitotic cells and utilizing flow cytometry. Using Western blotting, the activation of certain key players in the antephase and G2 checkpoint was revealed. MTT assays were performed to show the outcome of checkpoint activation. / Results: In HCT116 cells, 35 genes that facilitate G2/M transition were found to be up-regulated after R,R-5 treatment compared with oxaliplatin in the microarray analysis, implying the bypass of mitotic checkpoints by R,R-5 rather than oxaliplatin. Acute stress (2 hour) of cisplatin activated the antephase checkpoint, resulting in a rapid decrease in mitotic index and phosphorylation of histone H1, which avoided mitotic catastrophe and promoted cell survival in HeLa cells. Further experiments demonstrated that this antephase checkpoint could be abrogated by c-Abl and p38MAPK inhibitors, or siRNAs against c-Abl or MEKK1, suggesting that this checkpoint may be controlled by an MMR/c-Abl/MEKK1/p38MAPK pathway. In contrast, oxaliplatin and R,R-5 did not activate this antephase checkpoint. Moreover, after 24 hour oxaliplatin treatment in HeLa cells, the mitotic index and CDK1 activity were decreased, which could be restored by concomitant treatment with ATM/ATR inhibitor and DMC. This indicated the activation of G2 checkpoint by oxaliplatin and implied that DMC can abrogate oxaliplatin-activated G2 checkpoint by restoring CDK1 activity. Cisplatin could also activate G2 checkpoint, whereas R,R-5 apparently bypassed this G2 checkpoint. / Guan, Huaji. / Adviser: Vincent Hon Leung Lee. / Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: . / Thesis (Ph.D.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves 212-249). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. Ann Arbor, MI : ProQuest Information and Learning Company, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. Ann Arbor, MI : ProQuest Information and Learning Company, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

L'exigence principale du cycle cellulaire est une coordination étroite entre l'achèvement du processus de réplication et l'entrée des cellules en mitose, afin de maintenir l'intégrité génétique, l'identité et à la survie cellulaire. Toutes les cellules somatiques exécutent de manière reproductible une phase G2 intermédiaire, d'une durée constante pendant les divisions cellulaires successives au sein d'un type cellulaire donné. Cependant, les mécanismes moléculaires qui contrôlent précisément sa durée au cours d'un cycle cellulaire non perturbé, restent mal caractérisés. La kinase Cycline B1-Cdk1, facteur universel permettant l'entrée en mitose, est sous le contrôle, chez les mammifères, d'un ensemble de régulateurs directs, les kinases inhibitrices Wee1 et Myt1 et les phosphatases activatrices Cdc25A, B et C. Son activation soudaine, en fin de phase G2, révèle qu'une modification rapide de l'équilibre entre ses régulateurs opposés prend place par des mécanismes moléculaires qui restent à élucider. Dans ce cadre, j'ai étudié le rôle potentiel de la kinase Polo-like kinase 1 (Plk1) pour l'initiation de l'activation de Cycline B1-Cdk1. Bien que les rôles de Plk1 au cours de la mitose soient bien caractérisés, sa contribution dans la régulation de l'entrée des cellules en mitose reste controversée. Au niveau moléculaire, Plk1 phosphoryle au moins in vitro, plusieurs régulateurs de Cycline B1-Cdk1, tels que Cdc25B & C, et Wee1 et Myt1. Cependant, il reste largement inconnu si ces événements de phosphorylation se produisent in vivo et s'ils contribuent de manière significative au processus de l'activation de Cycline B1-Cdk1 permettant l'entrée en mitose. / A main requirement of the cell cycle is a tight coordination between the completion of the replication process and entry into mitosis in order to maintain genetic integrity and the identity and survival of cell progeny. All somatic cells reproducibly execute an intermediate G2 phase of constant duration during successive cell divisions in a given cell type. However the molecular mechanisms controlling precisely its duration during unperturbed cell cycle remains poorly characterized. In this context, the main objective of my PhD project was to decipher signaling pathways controlling entry into mitosis during normal cell cycles as well as their spatiotemporal regulation. CyclinB1-Cdk1, the universal master mitotic driver, is under the control of direct inhibitors (Wee1 and Myt1) and activators (Cdc25A, B and C). Previously, it was determined that CyclinB1-Cdk1 is suddenly activated in very late G2 phase, suggesting that a rapid modification in the equilibrium between its opposite regulators is reproducibly taking place in late G2 by poorly elucidated mechanisms. During my PhD, I investigated the potential role of Polo-like kinase 1 (Plk1) in the initial activation of CyclinB1-Cdk1. Even though its roles during mitosis are well characterized, its contribution for the regulation of entry into mitosis remains controversial. At the molecular level, Plk1 was shown to phosphorylate at least in vitro, several regulators of CyclinB1-Cdk1 including Cdc25B&C, and Wee1 and Myt1. However, it remains largely unknown if these phosphorylation events are taking place in vivo and whether they significantly contribute to the activation process of CyclinB1-Cdk1 leading to mitotic entry.

No description available.